Cost of Immunotherapy for Head and Neck Cancer — The Real Numbers, and Who Is Actually Eligible

Most people in India with head and neck cancer are not candidates. Immunotherapy is not part of standard curative-intent treatment for newly diagnosed, locally advanced disease. Checkpoint inhibitors are used mainly for squamous-cell head and neck cancer that has come back or has spread, and can no longer be removed by surgery.

• The standard path is surgery, radiation and chemotherapy — for a newly diagnosed head and neck cancer treated with curative intent, these remain the treatments that matter, given on time and in the right order (NCCN Head and Neck Cancers guidance).
• Checkpoint inhibitors sit later in the pathway — the approved setting is recurrent or metastatic squamous-cell disease, either as first treatment for that stage or after platinum-based chemotherapy has been used.
• A tissue test usually decides the shape of it — a PD-L1 score, reported as a Combined Positive Score (CPS) on your biopsy or surgical specimen, is used to judge whether a checkpoint inhibitor alone is reasonable or whether it should be combined with chemotherapy.
• Not every head and neck cancer follows the same rule — nasopharyngeal, salivary-gland and thyroid cancers are different diseases with different evidence, and what applies to oral or laryngeal squamous-cell cancer does not automatically apply to them.
• Fitness and immune history can rule it out — an active autoimmune condition, ongoing high-dose steroids, an organ transplant or a poor performance status can make a checkpoint inhibitor unsafe regardless of the tumour test result.

A cycle is priced by the drug, not by the cancer type. As of August 2026, the indicative drug cost for one cycle is roughly ₹50,000 to ₹1,50,000 for a domestically manufactured or biosimilar checkpoint inhibitor, and roughly ₹2,00,000 to ₹4,50,000 for an imported reference product. Day care and tests add a little more.

All figures are indicative only, as of August 2026, and are quoted by product class rather than by brand. The real number depends on the product selected, whether the dose is flat or calculated by body weight, the cycle interval and the centre. Immunotherapy is given as day care at CION centres, so a routine cycle carries no inpatient bed charge.

There is no single full-course price, because the length is not fixed in advance. Treatment continues until the cancer progresses, until a side effect makes it unsafe, or up to a planned ceiling of about two years. Multiply the per-cycle band by the number of cycles you are planning for.

These are drug costs only, indicative as of August 2026. Add day-care administration and pre-cycle blood tests for every cycle. Add a response-assessment scan roughly every eight to twelve weeks — response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION, and runs roughly ₹10,000 – ₹25,000 per scan depending on the scan type, indicative as of August 2026.

Aarogyasri, Ayushman Bharat PM-JAY, CGHS, ECHS and ESI all work to fixed package ceilings. High-cost immunotherapy drugs commonly sit above those ceilings, so cover is often partial or absent. Private insurance usually pays for day-care infusion, subject to sub-limits and pre-authorisation. None of this is a promise of cover.

• Aarogyasri (Telangana and Andhra Pradesh) — head and neck surgery, radiation and chemotherapy packages are well established. High-cost immunotherapy sits in a different bracket, so ask the hospital scheme desk for the current ceiling in writing.
• Ayushman Bharat PM-JAY — the same package-ceiling logic applies nationally. What the scheme does and does not reach is set out on Ayushman Bharat and immunotherapy coverage.
• CGHS, ECHS and ESI — these run on approved rate lists plus prior approval. The approval step often takes longer than the gap between two cycles, so begin the paperwork before treatment starts, not between cycles.
• Private health insurance — day-care infusion is payable under most modern policies, but sub-limits, waiting periods, pre-existing-disease clauses and pre-authorisation rules decide what you actually receive.
• Manufacturer access programmes — several manufacturers run patient-assistance or dose-support programmes in India. Eligibility varies, documentation takes time, and applications usually have to be made before cycle one.
• Choosing a domestic or biosimilar product — usually the largest single reduction available, and a clinical conversation to have with your oncologist rather than a decision to make on your own.

Head and neck cancer brings costs no drug price list shows. Swallowing difficulty, mouth care, dental review and nutrition support are common. Travelling to a day-care centre every three weeks is a real household expense. Budget for these alongside the cycle bill rather than discovering them in month three.

Ask for an itemised estimate before the first cycle that separates the drug from everything else, and ask what happens to that estimate if an immune-related side effect needs treating. A quote that arrives as one number with no breakdown is not yet an estimate you can plan a year around. Eligibility in other cancers is gated the same way, by a test result rather than by hope — Immunotherapy for Colorectal Cancer: Only If You Are MSI-High is the sharpest version of that rule.

Every cancer type gates immunotherapy differently, and the gate is what decides whether cost is even a question for you. These pages cover how eligibility is decided in three other cancers, and how the treatment pathway itself is run.

• Immunotherapy for Kidney Cancer: The New Standard — the cancer where checkpoint inhibitors moved earliest into routine practice, and how that changes the cost conversation.
• Immunotherapy for Colorectal Cancer: Only If You Are MSI-High — a single lab result decides eligibility, which makes it the clearest example of testing before spending.
• Immunotherapy for Breast Cancer: Who Is Actually Eligible — another cancer where the honest answer for most patients is that this is not their treatment.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, side-effect monitoring and cost counselling run as one pathway.

Decisions for Healing, Not Billing

Cost is discussed openly at the first consultation — including the option of not starting immunotherapy at all if the numbers do not work for your family.